Unigestion Holding SA decreased its holdings in Zoetis Inc (NYSE:ZTS) by 43.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,590 shares of the company’s stock after selling 41,198 shares during the quarter. Unigestion Holding SA’s holdings in Zoetis were worth $4,999,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Polen Capital Management LLC grew its stake in shares of Zoetis by 3.9% in the second quarter. Polen Capital Management LLC now owns 9,295,080 shares of the company’s stock worth $791,848,000 after purchasing an additional 351,447 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Zoetis by 1.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 7,692,247 shares of the company’s stock worth $704,302,000 after purchasing an additional 119,154 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Zoetis by 9.1% in the second quarter. Wells Fargo & Company MN now owns 6,375,146 shares of the company’s stock worth $543,099,000 after purchasing an additional 529,666 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Zoetis by 22.3% in the second quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock worth $460,890,000 after purchasing an additional 985,586 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Zoetis by 8.7% in the second quarter. Bank of New York Mellon Corp now owns 5,262,461 shares of the company’s stock worth $448,309,000 after purchasing an additional 422,856 shares during the last quarter. 89.68% of the stock is currently owned by institutional investors.

In other news, insider Catherine A. Knupp sold 46,816 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $90.84, for a total transaction of $4,252,765.44. Following the transaction, the insider now owns 81,640 shares in the company, valued at $7,416,177.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Juan Ramon Alaix sold 150,306 shares of the company’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $94.96, for a total transaction of $14,273,057.76. Following the transaction, the chief executive officer now owns 246,319 shares in the company, valued at approximately $23,390,452.24. The disclosure for this sale can be found here. Insiders have sold 350,507 shares of company stock worth $32,579,830 in the last ninety days. Insiders own 0.35% of the company’s stock.

Several analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $100.00 to $101.00 and gave the stock an “overweight” rating in a research note on Friday, November 2nd. Morgan Stanley set a $100.00 price objective on shares of Zoetis and gave the stock a “hold” rating in a research note on Friday, November 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $105.00 price objective (up previously from $98.00) on shares of Zoetis in a research note on Wednesday, October 17th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Wednesday, October 17th. Finally, Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price objective on the stock. in a research note on Tuesday, August 21st. They noted that the move was a valuation call. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $93.19.

Shares of ZTS opened at $95.27 on Friday. The company has a current ratio of 4.06, a quick ratio of 2.63 and a debt-to-equity ratio of 3.04. The firm has a market cap of $45.73 billion, a price-to-earnings ratio of 31.31, a PEG ratio of 1.87 and a beta of 0.97. Zoetis Inc has a 12 month low of $68.56 and a 12 month high of $96.57.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, November 1st. The company reported $0.83 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.06. The business had revenue of $1.48 billion for the quarter, compared to analysts’ expectations of $1.46 billion. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.65 earnings per share. As a group, sell-side analysts predict that Zoetis Inc will post 3.11 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be given a dividend of $0.126 per share. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.53%. Zoetis’s dividend payout ratio (DPR) is currently 20.83%.

COPYRIGHT VIOLATION WARNING: This report was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://theolympiareport.com/2018/11/10/unigestion-holding-sa-has-5-million-position-in-zoetis-inc-zts.html.

About Zoetis

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Featured Story: How is inflation measured?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.